Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
about
Targeting the hepatocyte growth factor-cMET axis in cancer therapyMonovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentDrug development against metastasis-related genes and their pathways: A rationale for cancer therapyEndocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration.Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyThe Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in CancerNew radiotracers for imaging of vascular targets in angiogenesis-related diseases.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibodyDeletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancerThe hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancerAptamers Binding to c-Met Inhibiting Tumor Cell MigrationTIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial ProgramTargeting the HGF/Met signalling pathway in cancer.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Flexibility and small pockets at protein-protein interfaces: New insights into druggability.A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of MetActivity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapyDNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.Targeting the HGF/Met signaling pathway in cancer therapyAnti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growthDown-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.Decorin is a novel antagonistic ligand of the Met receptor.Targeted therapy for malignant glioma patients: lessons learned and the road ahead.c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.Clinical implications of MET gene copy number in lung cancer.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Targeting the MET oncogene in cancer and metastases.Paradoxical action of growth factors: antiproliferative and proapoptotic signaling by HGF/c-MET.Role of MetMAb (OA-5D5) in c-MET active lung malignancies.c-MET as a potential therapeutic target and biomarker in cancer.Targeting the Met pathway in lung cancer.
P2860
Q24606259-61845E92-6C33-438B-BAEB-8D04B854DB06Q27679191-95067BA0-E3A8-4EEF-98CB-409B83593FF2Q29010479-96B87E79-F6FE-4C22-AE0C-5315ACCDF33FQ30479942-B1ED2C75-127F-47D2-B09B-CC7F4B9B4840Q33523441-2D3F6C52-1A6B-4EA1-A05E-FE05A1838809Q33652455-FBE03695-93CC-49E1-9999-6AD77EEA564DQ33828409-4A063F8D-9810-457E-BD18-13E41D542F9BQ34141913-BC44D727-095E-4F52-880B-12EBAC45A493Q34216877-3FF6158F-1F22-4A67-AF96-E50B9AB63BF8Q34236834-A33B79FA-C130-4872-A859-A6D31CDC5ECDQ34285473-308001F7-A6F4-438F-AC33-50F038526760Q34405019-C5B101CB-C2D6-4030-9500-A8A6C78F866DQ34786471-032ACBF2-15DF-4BCD-94DF-A70930410CA5Q35563524-0E8927B1-78C5-4913-BDEC-324D303A67C3Q35832938-DF5593FB-3C3C-4375-A80C-F4D758ACDA80Q35866739-97CBBFF8-6A82-4876-8CFC-DE4EFFEC0419Q36067201-FCC3986A-1891-40FC-B95C-C627A59B03A9Q36113481-1A48557B-3862-459E-AA29-6D0B41D060DFQ36133180-51B48456-DD90-427E-8EF5-41A07F41A9EBQ36142604-56477F8E-398A-4845-B898-6A8E0F8A7AD7Q36411841-06C84DCB-B7A3-43AA-8BF2-858FFF4EE4D9Q36501662-156B4BAD-827E-4BF0-9916-EF13B34E2145Q36777999-C9692108-F792-49A8-ACDD-9A5ACDDA1DF4Q36822111-638A23C6-058B-464F-98E2-8A222F0E2688Q36828371-822886F3-64F2-4BB0-AD02-38C40115D142Q36868117-72A24C34-EF49-4A14-8BEC-936C2FE8E2CFQ37013777-F3D295FD-4CA7-4EC1-8BDE-A4C80FE37EA1Q37138521-302A0664-5952-4AC2-BC3D-E4E49C0F80A3Q37175416-3072502F-58B7-45DA-BBBD-D5C7B6550856Q37263981-47497543-F665-4262-A94E-32C79C36FB2FQ37533648-604B38C7-52A6-4C6A-B6FF-4123F1CE4635Q37651008-AB259AC2-2A3A-4489-9253-58F6D60C8CB7Q37690299-C1937CAA-BAA5-4384-9297-353EE68BC80EQ37730020-16BCBA21-C697-4361-9327-03BECF1939BFQ37739477-C91280B0-E046-4740-8668-A916CAAA47D8Q37792116-9037046B-FB2E-4C6C-998D-D82FAAD82304Q37883394-2321E3B3-7E4B-437A-814B-EF5F21703A6CQ37952015-5DA03F50-9FC6-4B51-A6A8-7FD6B7ACDA87Q37962905-FA51F3A7-A2B0-4595-A7B8-A9B9334E6771Q38002473-F587AB6A-6CE8-412F-85DD-89221D98E094
P2860
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Ab-induced ectodomain shedding ...... nd hampers biological activity
@ast
Ab-induced ectodomain shedding ...... nd hampers biological activity
@en
Ab-induced ectodomain shedding ...... nd hampers biological activity
@nl
type
label
Ab-induced ectodomain shedding ...... nd hampers biological activity
@ast
Ab-induced ectodomain shedding ...... nd hampers biological activity
@en
Ab-induced ectodomain shedding ...... nd hampers biological activity
@nl
prefLabel
Ab-induced ectodomain shedding ...... nd hampers biological activity
@ast
Ab-induced ectodomain shedding ...... nd hampers biological activity
@en
Ab-induced ectodomain shedding ...... nd hampers biological activity
@nl
P2093
P2860
P50
P3181
P356
P1476
Ab-induced ectodomain shedding ...... nd hampers biological activity
@en
P2093
Alberto Pisacane
Annalisa Petrelli
Luisa Granziero
Paola Circosta
Silvia Fenoglio
P2860
P304
P3181
P356
10.1073/PNAS.0508156103
P407
P577
2006-03-28T00:00:00Z